Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sarepta Therapeutics, Inc. (SRPT)
Price$22.50Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.86B | $1.79B | $1.14B | $843.8M | $612.4M | $455.9M | $380.8M | $301.0M | $154.6M | $5.4M | $1.3M | $9.8M | $14.2M | $37.3M | $47.0M | $29.4M | — |
| Gross profit | $1.84B | $1.58B | $1.09B | $793.0M | — | — | — | — | — | $5.3M | — | — | — | — | — | — | — |
| Gross margin | 98.63% | 88.53% | 95.47% | 93.99% | — | — | — | — | — | 97.60% | — | — | — | — | — | — | — |
| Research & development | $1.52B | $804.5M | $877.4M | $877.1M | $771.2M | $722.3M | $560.9M | $401.8M | $166.7M | $188.3M | $146.4M | $94.2M | $72.9M | $52.4M | $66.9M | $36.0M | $24.4M |
| Operating expenses | $2.54B | $1.36B | $1.36B | $1.33B | — | — | $1.09B | $644.7M | $326.2M | $272.2M | $221.4M | $143.5M | $104.5M | $67.0M | — | — | — |
| Operating income | −$699.8M | $218.1M | −$267.8M | −$536.2M | −$459.7M | −$564.2M | −$705.6M | −$343.6M | −$171.6M | −$266.7M | −$220.2M | −$133.8M | −$90.3M | −$29.7M | −$35.9M | −$20.9M | −$15.5M |
| Operating margin | −37.54% | 12.20% | −23.39% | −63.55% | −75.07% | −123.76% | −185.27% | −114.15% | −111.03% | −4,920.31% | −17,572.55% | −1,371.21% | −634.95% | −79.57% | −76.46% | −71.16% | — |
| EBITDA | −$655.3M | $255.8M | −$223.4M | −$494.3M | −$421.7M | −$537.3M | −$681.1M | −$331.4M | −$163.5M | −$261.1M | −$214.9M | −$130.1M | −$89.0M | −$28.2M | −$34.6M | −$19.5M | −$14.1M |
| EBITDA margin | −35.15% | 14.31% | −19.52% | −58.59% | −68.86% | −117.85% | −178.84% | −110.08% | −105.80% | −4,816.81% | −17,153.79% | −1,333.39% | −625.97% | −75.49% | −73.69% | −66.18% | — |
| Net income | −$713.4M | $235.2M | −$536.0M | −$703.5M | −$418.8M | −$554.1M | −$715.1M | −$361.9M | −$50.7M | −$267.3M | −$220.0M | −$135.8M | −$112.0M | −$121.3M | −$2.3M | −$32.2M | −$25.2M |
| Net profit margin | −38.27% | 13.16% | −46.82% | −83.37% | −68.38% | −121.56% | −187.77% | −120.22% | −32.79% | −4,930.18% | −17,560.26% | −1,391.71% | −787.57% | −324.91% | −4.93% | −109.37% | — |
| Basic EPSper basic share | -$7.13 | $2.47 | -$5.80 | -$8.03 | -$5.15 | -$7.11 | -$9.71 | -$5.46 | -$0.86 | -$5.49 | -$5.20 | -$3.39 | -$3.31 | -$5.14 | -$0.12 | -$1.74 | -$1.62 |
| Diluted EPSper diluted share | -$7.13 | $2.34 | -$5.80 | -$8.03 | -$5.15 | -$7.11 | -$9.71 | -$5.46 | -$0.86 | -$5.49 | -$5.20 | -$3.39 | -$3.31 | -$5.14 | -$0.12 | -$1.74 | -$1.62 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 12, 2026Form 4 | Mayo StephenDirector | SellCommon Stock | 7.2K | $17.02 | $123.2K | 1.8K |
| Dec 16, 2025Form 4 | Estepan Ian MichaelChief Operating Officer | SellCommon Stock | 13.2K | $22.31 | $294.2K | 193.3K |
| Mar 12, 2025Form 4 | Nicaise ClaudeDirector | SellCommon Stock | 2.5K | $99.64 | $248.2K | 27.8K |
| Dec 12, 2024Form 4 | Wigzell Hans Lennart RudolfDirector | SellCommon Stock | 10.5K | $124.84 | $1.31M | 22.8K |
| Dec 5, 2024Form 4 | Boor Kathryn JeanDirector | SellCommon Stock | 1.6K | $125.55 | $205.4K | 5.9K |
Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...